Why Choose Private Prescription for Wegovy and Mounjaro?
Private vs NHS Routes for Wegovy Mounjaro Access
The NHS pathway for accessing Wegovy or Mounjaro involves GP referral to specialist weight management services, often resulting in 6+ month waiting periods before treatment consideration. Private prescription eliminates these delays through direct clinical assessment, making both wegovy mounjaro options immediately available to eligible patients. Our streamlined process requires no GP referral - simply complete a 3-minute online assessment reviewed by qualified prescribers within 24-48 hours.
Private prescription ensures access to the same genuine medications dispensed through NHS services, manufactured by Novo Nordisk (Wegovy) and Eli Lilly (Mounjaro). The key difference lies in accessibility and speed rather than medication quality, allowing patients to begin their weight management journey without extended delays. Both wegovy mounjaro treatments require the same clinical assessment standards, ensuring appropriate patient selection regardless of prescription route.
Wegovy Mounjaro Pricing and Bundle Options
Wegovy pricing begins at £79.99 for the 0.25mg starter dose, progressing through £94.99 (0.5mg), £99.99 (1mg), £139.99 (1.7mg), to £209.99 for the 2.4mg maintenance dose. New customers apply discount code FIRST40 at checkout to reach these final prices, whilst returning customers use code DOSE25. Bundle options provide convenient multi-month supplies, such as the Intro Trio (0.25mg, 0.5mg, 1mg) for £299.99 covering the first 12 weeks of treatment.
Mounjaro follows a similar pricing structure with dose-specific costs reflecting the medication's dual GIP/GLP-1 receptor mechanism. Both wegovy mounjaro treatments offer 2-pen and 3-pen bundles designed for convenience rather than savings, ensuring uninterrupted supply during dose escalation phases. All prices include VAT and next-day delivery once prescriber approval is confirmed, with cold-chain storage maintaining medication integrity throughout transport.
Clinical Evidence Behind Wegovy Mounjaro Effectiveness
Wegovy demonstrated significant weight reduction in the landmark STEP trial programme, with participants achieving approximately 15% average weight loss at 68 weeks when combined with lifestyle interventions (Wilding et al., NEJM, 2021). The STEP 5 extension study confirmed sustained weight management benefits over 2 years, whilst SELECT cardiovascular outcomes data showed 20% reduction in major cardiovascular events.
Mounjaro's SURMOUNT clinical programme evaluated tirzepatide's dual GIP/GLP-1 receptor agonist mechanism in weight management applications. Both wegovy mounjaro treatments require combination with reduced-calorie diets and increased physical activity to achieve optimal outcomes, as demonstrated across their respective clinical development programmes. Individual results may vary based on adherence, lifestyle factors, and patient-specific characteristics.
How Wegovy Works in Weight Management
Wegovy contains semaglutide, a GLP-1 receptor agonist that mimics natural incretin hormones regulating appetite and food intake. The medication works by slowing gastric emptying, promoting satiety after smaller meals, and potentially reducing food cravings through actions on brain appetite centres. These mechanisms combine to support caloric reduction when used alongside prescribed diet and exercise modifications. Wegovy's once-weekly injection schedule using the FlexTouch pen system provides consistent therapeutic levels throughout the week. The mandatory dose escalation protocol - 0.25mg, 0.5mg, 1mg, 1.7mg, then 2.4mg maintenance - allows gradual tolerance development whilst minimising gastrointestinal side effects commonly associated with GLP-1 receptor agonists.
Ordering Process for Wegovy Mounjaro Private Prescription
The private prescription process begins with a comprehensive 3-minute clinical assessment covering medical history, current medications, weight management goals, and contraindication screening. Qualified prescribers review submissions within standard 3 working days (or 24 hours with express service), ensuring appropriate patient selection for either wegovy mounjaro treatment options. Upon approval, our GPhC-registered pharmacy (#9012878) dispatches medications via next-day delivery using temperature-controlled cold-chain logistics. All shipments include injection technique guidance, storage instructions, and 24/7 clinical support contact details for ongoing treatment queries. Prescription validity covers the specific dose prescribed, with follow-up assessments required for dose escalations or treatment continuation beyond initial supply periods.
Storage and Practical Considerations for Wegovy Mounjaro
Both wegovy mounjaro treatments require refrigerated storage at 2-8°C before first use, though Wegovy offers superior travel convenience with 6 weeks room temperature stability versus Mounjaro's 21-day limit once removed from refrigeration. The FlexTouch pen system (Wegovy) and KwikPen system (Mounjaro) feature pre-filled, single-use designs requiring weekly subcutaneous injection into thigh, abdomen, or upper arm rotation sites. Dose escalation cannot be skipped or accelerated, as the graduated increase minimises gastrointestinal side effects whilst allowing therapeutic adaptation. Unused pens should never be frozen or exposed to direct sunlight, and patients must inspect solutions for clarity before each injection. Both treatments are classified as prescription-only medicines requiring ongoing clinical supervision throughout the treatment duration.
Wegovy Mounjaro Mechanism Differences for Private Patients
Private prescription allows detailed discussion of the mechanistic differences between wegovy mounjaro options during prescriber consultation. Wegovy's selective GLP-1 receptor agonism provides proven weight management efficacy through single-pathway activation, whilst Mounjaro's dual GIP/GLP-1 receptor mechanism offers potentially enhanced metabolic effects through complementary hormone pathway stimulation. These mechanistic distinctions may influence prescriber recommendations based on individual patient profiles, metabolic status, and treatment response history.
Private consultation time permits thorough evaluation of patient preferences regarding injection frequency, storage requirements, and dose escalation schedules when choosing between wegovy mounjaro alternatives. The absence of NHS formulary restrictions allows prescribers to prioritise clinical suitability over cost considerations, ensuring optimal treatment selection based purely on patient-specific factors rather than budgetary constraints.
Start Your Wegovy Mounjaro Journey Today
Both wegovy mounjaro treatments are immediately available through our private prescription service, eliminating NHS waiting lists whilst maintaining the same high-quality medications and clinical oversight standards. New customers receive discount code FIRST40 at checkout, whilst returning patients apply DOSE25 for continued savings on subsequent orders. Complete your clinical assessment at https://everydaymeds.co.uk/collections/wegovy to begin treatment within days rather than months. Our qualified prescribers will determine the most suitable option based on your individual circumstances, medical history, and weight management objectives. Remember that both treatments work most effectively when combined with sustainable lifestyle modifications including reduced-calorie nutrition and regular physical activity.
Reviewed by the EverydayMeds Clinical Team · GPhC #9012878 · Last updated February 2026
